TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26001318

Group type: COMPARATOR
Intervention: Remifentanil infusion at nil μg kg(‐1) min(‐1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.05 μg kg(‐1) min(‐1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.10 μg kg(‐1) min(‐1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.15 μg kg(‐1) min(‐1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.20 μg kg(‐1) min(‐1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.25 μg kg(‐1) min(‐1)
Number of subjects: 108
Study: 23379836

Group type: EXPERIMENTAL
Intervention: Gold 8-mm-tip ablation
Number of subjects: 428

Group type: COMPARATOR
Intervention: Platinum-iridium 8-mm-tip ablation
Number of subjects: 428
Study: 21723781

Group type: EXPERIMENTAL
Intervention: Extra-pleural pneumonectomy (EPP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No extra-pleural pneumonectomy (no EPP)
Number of subjects: 50
Study: 19010636

Group type: EXPERIMENTAL
Intervention: 4 cc fibrin glue after RILND
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline 0.9 percent irrigation
Number of subjects: 58
Study: 17523990

Group type: EXPERIMENTAL
Intervention: Personalized Feedback (PF)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Multi-media Feedback (MMF)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Delayed Feedback Control (DFC)
Number of subjects: 188
Study: 14747423

Group type: EXPERIMENTAL
Intervention: Quinapril (high-tissue-penetrating ACE inhibitor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril (low-tissue-penetrating ACE inhibitor)
Number of subjects: 30
Study: 11392657

Group type: EXPERIMENTAL
Intervention: Regular rehabilitation with supported treadmill ambulation training (STAT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular rehabilitation (REG)
Number of subjects: 12
Study: 9717012

Group type: EXPERIMENTAL
Intervention: Exercise training (bicycle training at 80% of maximal intensity for 4 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 7946861

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane anaesthesia
Number of subjects: 20
Study: 1842749

Group type: EXPERIMENTAL
Intervention: Miglitol, 50 mg three times a day
Number of subjects: 39
Study: 342626

Group type: EXPERIMENTAL
Intervention: Whole-virus bivalent influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ether-split bivalent influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mass influenza vaccination program
Number of subjects: 0
Study: 30907881

Group type: EXPERIMENTAL
Intervention: Video demonstration on PA intensity levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (PA assessment only)
Number of subjects: 0
Study: 27883203

Group type: EXPERIMENTAL
Intervention: Platform-switched implant-abutment connection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional platform-matched implant-abutment connection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 80
Study: 26032852

Group type: EXPERIMENTAL
Intervention: PLISSIT model intervention (sexual counselling from general practitioner)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23681934

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 352
Study: 16787931

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Regional Analgesia (PCRA) with ropivacaine 0.2%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous Regional Analgesia (CRA) with ropivacaine 0.2%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both PCRA and CRA
Number of subjects: 30
Study: 15195074

Group type: EXPERIMENTAL
Intervention: Busulphan (BU) 150 mg/m2 given as four single daily doses
Number of subjects: 63

Group type: COMPARATOR
Intervention: Busulphan (BU) 4 mg/kg given as four single daily doses
Number of subjects: 63
Study: 10367611

Group type: EXPERIMENTAL
Intervention: Active antihypertensive medication
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8889266

Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1323811

Group type: EXPERIMENTAL
Intervention: Etoposide/Cisplatin (EP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative Cisplatin/Etoposide with concurrent thoracic irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum/Etoposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study: 6507909

Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride (5 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam maleate (2.5 mg/ml)
Number of subjects: 12
Study: 31326680

Group type: EXPERIMENTAL
Intervention: Single-lead handheld ECG screening for AF
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16000
Study: 28899524

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) adherence for six months
Number of subjects: 0
Study: 25349333

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 5794

Group type: COMPARATOR
Intervention: High CRP (>3 mg/L)
Number of subjects: 5794
Study: 23786930

Group type: EXPERIMENTAL
Intervention: SFC+M (salmeterol/futicasone plus montelukast)
Number of subjects: 38

Group type: COMPARATOR
Intervention: SFC (salmeterol/futicasone plus placebo)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SFC+M
Number of subjects: 38

Group type: COMPARATOR
Intervention: SFC
Number of subjects: 38
Study: 21784046

Group type: EXPERIMENTAL
Intervention: Individualized treatment (24-72 weeks)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard treatment (48 weeks)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Individualized treatment (24-30 weeks) for rapid responders
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Individualized treatment (60-72 weeks) for slow responders
Number of subjects: 398
Study: 19804620

Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Long-Lasting Insecticide Treated Nets (LLIN)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Environmental Management (EVM) - Mud Plastering
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Environmental Management (EVM) - Lime Plastering
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study: 17177749

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment with retinyl-based cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) treatment only
Number of subjects: 20
Study: 13679494

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tertatolol (5-10 mg/day)
Number of subjects: 48
Study: 11003207

Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption
Number of subjects: 209
Study: 8638692

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no rhGH treatment)
Number of subjects: 15
Study: 1420750

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (1.8 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg) b.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3973067

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Psychosocial treatment
Number of subjects: 43
Study: 30381138

Group type: EXPERIMENTAL
Intervention: Aprepitant 10 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control regimen of ondansetron
Number of subjects: 220
Study: 29894717

Group type: EXPERIMENTAL
Intervention: Automated/customized text messages and phone calls, followed by text message reminders
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Standard of care (written letter)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Text messages and reminders only
Number of subjects: 1220
Study: 27019280

Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: SPARX
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: OVK and SPARX combined
Number of subjects: 208

Group type: COMPARATOR
Intervention: Monitoring control condition
Number of subjects: 208
Study: 25087837

Group type: EXPERIMENTAL
Intervention: PRP + interactive videogame-aided exercises (EG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard PRP (CG)
Number of subjects: 40
Study: 22420526

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days
Number of subjects: 474

Group type: COMPARATOR
Intervention: Vehicle administered twice daily for 3 days
Number of subjects: 474
Study: 20137091

Group type: EXPERIMENTAL
Intervention: Pharmacist Care Group (PCG)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Hidden Control Group (HCG)
Number of subjects: 546
Study: 17432674

Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder (DXP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Maprotiline (Control)
Number of subjects: 63
Study: 16781589

Group type: EXPERIMENTAL
Intervention: Traumeel S ointment
Number of subjects: 357

Group type: COMPARATOR
Intervention: Diclofenac 1% gel
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 357
Study: 11871813

Group type: COMPARATOR
Intervention: Fibrin glue applied onto the surface of the leaking raw lung (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pedicled pericardial fat pad fixed with fibrin glue (Group B)
Number of subjects: 30
Study: 10429002

Group type: EXPERIMENTAL
Intervention: Cerebral ventriculomegaly (VM) at term
Number of subjects: 257

Group type: COMPARATOR
Intervention: No cerebral ventriculomegaly (VM)
Number of subjects: 257
Study: 7742723

Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg) daily for 6 months
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo (similar-appearing) daily for 6 months
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 2201724

Group type: EXPERIMENTAL
Intervention: Triazolam (TRZ, 0.25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zopiclone (ZOP, 7.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triazolam (TRZ, 0.25 mg) + Alcohol (0.8 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zopiclone (ZOP, 7.5 mg) + Alcohol (0.8 g/kg)
Number of subjects: 12
Study: 7018605

Group type: COMPARATOR
Intervention: Standard formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative formulation
Number of subjects: 0
Study: 31870424

Group type: EXPERIMENTAL
Intervention: Individual guidance on restricting dietary salt intake by a physician
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine treatment only
Number of subjects: 200
Study: 27940395

Group type: EXPERIMENTAL
Intervention: Gynaecological teaching associates (GTAs)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Conventional pelvic manikin based teaching
Number of subjects: 492
Study: 25903195

Group type: EXPERIMENTAL
Intervention: Home-based moderate intensity walking intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 23337606

Group type: EXPERIMENTAL
Intervention: M‐Entropy monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 50
Study: 21343219

Group type: EXPERIMENTAL
Intervention: Chronic disease self-management intervention implemented by nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 19702927

Group type: EXPERIMENTAL
Intervention: Family‐focused therapy (FFT)
Number of subjects: 10
Study: 17931576

Group type: EXPERIMENTAL
Intervention: Internet-based interactive training using video modeling and mastery learning instructional design
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 15480372

Group type: EXPERIMENTAL
Intervention: Intervention group (hand washing, glove use, avoiding intimate contact)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intervention group (for women attempting pregnancy with a child shedding CMV)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (for women already pregnant at enrollment)
Number of subjects: 166
Study: 11509190

Group type: EXPERIMENTAL
Intervention: Smoked marijuana (8.4 and 16.9 mg THC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 13
Study: 9146840

Group type: EXPERIMENTAL
Intervention: Malingering MS (informed)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Malingering MS (non-informed)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Malingering TBI (informed)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Malingering TBI (non-informed)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-malingering controls
Number of subjects: 69
Study: 8131435

Group type: EXPERIMENTAL
Intervention: Refeeding via nasoenteric tube
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 10
Study: 3312933

Group type: EXPERIMENTAL
Intervention: Boiled coffee
Number of subjects: 42

Group type: COMPARATOR
Intervention: Filtered coffee
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tea
Number of subjects: 42
Study: 31189655

Group type: EXPERIMENTAL
Intervention: Milk polar lipids (3 or 5 g-PL/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Milk polar lipids (5 g-PL/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Milk polar lipids
Number of subjects: 58
Study: 30104806

Group type: EXPERIMENTAL
Intervention: As-needed endotracheal suctioning protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine endotracheal suctioning protocol
Number of subjects: 90
Study: 27609846

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous parecoxib sodium followed by oral celecoxib
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo with opioids as rescue treatment
Number of subjects: 246
Study: 25907853

Group type: EXPERIMENTAL
Intervention: ICARUSS model of integrated care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study: 23725316

Group type: EXPERIMENTAL
Intervention: Conventional caries management with best practice prevention
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Biological management of caries with best practice prevention
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Best practice prevention alone
Number of subjects: 1461
Study: 20578610

Group type: EXPERIMENTAL
Intervention: Clonidine tablet at the dose of 5 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 60
Study: 18400709

Group type: EXPERIMENTAL
Intervention: Dark chocolate and cocoa (37-g dark chocolate bar and 8 ounces of artificially sweetened cocoa beverage daily for 6 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (similar placebo products daily for 6 weeks)
Number of subjects: 101
Study: 16102908

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12527318

Group type: EXPERIMENTAL
Intervention: Painful infusion of hypertonic saline in the FDI muscle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pain combined with dual stimulation (electrical stimulation of the FDI motor point paired with TMS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dual stimulation (electrical stimulation of the FDI motor point paired with TMS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Painful stimulation of the FDI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ulnar-evoked M-waves
Number of subjects: 10
Study: 10588558

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amantadine (2.5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8906985

Group type: EXPERIMENTAL
Intervention: Randomized trials with increased sample sizes over time
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Trials in gastroenterology, cardiology, or oncology
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Trials with binary outcomes
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Trials with significant results
Number of subjects: 386
Study: 1748037

Group type: EXPERIMENTAL
Intervention: Billroth II gastrectomy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrectomy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Billroth II gastrectomy with persistent HP infection
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 22
Study: 7107083

Group type: EXPERIMENTAL
Intervention: Cephapirin
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Methicillin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 217
Study: 3987769

Group type: EXPERIMENTAL
Intervention: Dry salbutamol powder (400 micrograms)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pressurized salbutamol aerosol (200 micrograms)
Number of subjects: 22
Study: 29781900

Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (NAFL) treatment on one half of the face
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin (10 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAFL treatment
Number of subjects: 18
Study: 27046471

Group type: EXPERIMENTAL
Intervention: Biphasic Calcium Phosphate (BCP) combined with Platelet-Rich Plasma (PRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Demineralized Bovine Bone Matrix (DBBM) combined with Platelet-Rich Plasma (PRP)
Number of subjects: 20
Study: 23946152

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted danoprevir (DNVr) 100/100 mg twice/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methadone maintenance therapy (MMT) alone
Number of subjects: 18
Study: 22303473

Group type: EXPERIMENTAL
Intervention: Family meetings intervention (n=96)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care (n=96)
Number of subjects: 192
Study: 20393352

Group type: EXPERIMENTAL
Intervention: Back squat or hang clean (midthigh) with a load equal to their 5 repetition maximum (5RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4 or 5-minute rest interval after resistance exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ground reaction force (GRF) measurement
Number of subjects: 16
Study: 18758201

Group type: COMPARATOR
Intervention: OxyContin tablets (controlled‐release oxycodone hydrochloride: 5, 10, 20, and 40 mg)
Number of subjects: 0
Study: 15917111

Group type: EXPERIMENTAL
Intervention: PCECV (Purified Chick Embryo Cell Vaccine) administered intradermally at 0.1 mL with antigen corresponding to 0.32 IU per intramuscular dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current WHO recommendations for vaccine potency (2.5 IU per intramuscular dose)
Number of subjects: 0
Study: 12903979

Group type: EXPERIMENTAL
Intervention: Pumpkin (n = 6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Spinach (n = 8)
Number of subjects: 14
Study: 10327202

Group type: EXPERIMENTAL
Intervention: Illusory bar seen rotating with the inducing gratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illusory bar seen as a stationary and opaque tape
Number of subjects: 0
Study: 8600871

Group type: EXPERIMENTAL
Intervention: Home program of physical therapy (6-week program including ROM exercises, low resistance isometric and eccentric exercises of hip abductors)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no programs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Home program of physical therapy (all programs for group B)
Number of subjects: 23
Study: 1817942

Group type: EXPERIMENTAL
Intervention: Rectal Midazolam sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Midazolam sedation
Number of subjects: 0
Study: 7258126

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1.8 g daily for 10 children, 1.5 g daily for 10 children)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no supplemental ascorbic acid)
Number of subjects: 40
Study: 31173468

Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HBV (HBV DNA < 20 IU/mL after 48 weeks)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HCV (SVR-12)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Baseline PRO scores in HBV
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Post-treatment PRO scores
Number of subjects: 264